- Home
- EWTX
as 01-21-2025 4:00pm EST
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 2.6B | IPO Year: | 2021 |
| Target Price: | $44.83 | AVG Volume (30 days): | 818.6K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.90 - $38.12 | Next Earning Date: | 02-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Edgewise Therapeutics Inc. (EWTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Russell Alan J | EWTX | Chief Scientific Officer | Dec 30 '24 | Sell | $27.37 | 100,000 | $2,737,470.00 | 14,863 | |
| Semigran Marc | EWTX | Chief Development Officer | Dec 24 '24 | Sell | $29.87 | 29,709 | $881,915.22 | 8,445 |
Latest Edgewise Therapeutics Inc. News
EWTX Breaking Stock News: Dive into EWTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
Business Wire
9 days ago
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
Business Wire
15 days ago
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
MT Newswires
21 days ago
Edgewise Therapeutics Insider Sold Shares Worth $2,737,470, According to a Recent SEC Filing
Zacks
a month ago
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
Zacks
a month ago
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
Benzinga
a month ago
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
MT Newswires
a month ago
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Compare EWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EWTX Edgewise Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.